Aytu BioPharma Past Earnings Performance
Past criteria checks 0/6
Aytu BioPharma's earnings have been declining at an average annual rate of -18.8%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 41.8% per year.
Key information
-18.8%
Earnings growth rate
68.9%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 41.8% |
Return on equity | -54.8% |
Net Margin | -18.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Feb 17Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Feb 16Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Sep 29Aytu stock falls amid suspending clinical programs to save costs
Oct 13Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Sep 27Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Sep 14Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aug 16Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aug 09Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
May 19Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Sep 11Aytu BioPharma up 21% in afternoon trading
Jun 21Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now
May 15A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation
Feb 14Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts
Dec 31Aytu BioScience completes safety study in critically ill COVID-19 patients
Dec 28Aytu Bio raises 'bought deal' offering to $25M
Dec 11Aytu BioScience: The Barcode King Is Poised For An Epic Breakout
Nov 12Revenue & Expenses BreakdownBeta
How Aytu BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 98 | -18 | 60 | 2 |
30 Sep 23 | 102 | -24 | 67 | 4 |
30 Jun 23 | 107 | -17 | 70 | 4 |
31 Mar 23 | 104 | -32 | 73 | 9 |
31 Dec 22 | 106 | -77 | 71 | 9 |
30 Sep 22 | 102 | -82 | 70 | 12 |
30 Jun 22 | 97 | -109 | 70 | 13 |
31 Mar 22 | 93 | -112 | 73 | 14 |
31 Dec 21 | 82 | -84 | 68 | 11 |
30 Sep 21 | 74 | -82 | 62 | 7 |
30 Jun 21 | 66 | -58 | 56 | 6 |
31 Mar 21 | 57 | -42 | 47 | 2 |
31 Dec 20 | 52 | -22 | 42 | 2 |
30 Sep 20 | 40 | -13 | 37 | 2 |
30 Jun 20 | 28 | -14 | 31 | 2 |
31 Mar 20 | 14 | -25 | 24 | 0 |
31 Dec 19 | 9 | -24 | 22 | 0 |
30 Sep 19 | 7 | -29 | 21 | 1 |
30 Jun 19 | 7 | -27 | 19 | 1 |
31 Mar 19 | 7 | -12 | 18 | 1 |
31 Dec 18 | 5 | -10 | 18 | 1 |
30 Sep 18 | 4 | -9 | 17 | 0 |
30 Jun 18 | 4 | -10 | 18 | 0 |
31 Mar 18 | 4 | -17 | 17 | 0 |
31 Dec 17 | 4 | -20 | 17 | 1 |
30 Sep 17 | 4 | -21 | 16 | 1 |
30 Jun 17 | 3 | -23 | 17 | 1 |
31 Mar 17 | 3 | -31 | 17 | 4 |
31 Dec 16 | 3 | -33 | 15 | 5 |
30 Sep 16 | 3 | -32 | 13 | 6 |
30 Jun 16 | 3 | -28 | 9 | 6 |
31 Mar 16 | 2 | -15 | 7 | 4 |
31 Dec 15 | 1 | -10 | 6 | 4 |
30 Sep 15 | 1 | -8 | 5 | 3 |
30 Jun 15 | 0 | -8 | 4 | 3 |
31 Mar 15 | 0 | -7 | 4 | 4 |
31 Dec 14 | 0 | -7 | 3 | 4 |
30 Jun 14 | 0 | -6 | 2 | 4 |
31 Dec 13 | 0 | -4 | 2 | 3 |
30 Jun 13 | 0 | -3 | 1 | 3 |
Quality Earnings: AYTU is currently unprofitable.
Growing Profit Margin: AYTU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AYTU is unprofitable, and losses have increased over the past 5 years at a rate of 18.8% per year.
Accelerating Growth: Unable to compare AYTU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AYTU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: AYTU has a negative Return on Equity (-54.78%), as it is currently unprofitable.